ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Nilotinib, a second-generation BCR::ABL1 inhibitor, is primarily indicated for patients with chronic-phase or accelerated-phase CML who exhibit resistance or intolerance.